WHO Drug Information Vol. 24, No. 4, 2010

Proposed INN: List 104 WHO Drug Information, Vol. 24, No. 4, 2010ponezumabum #ponezumab immunoglobulin G2-kappa, anti-[Homo sapiens amyloid beta (Abeta) peptide Aβ40], humanized monoclonal antibody;gamma2 heavy chain (1-442) [humanized VH (Homo sapiensIGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -Homosapiens IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)],(130-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-30*01 (89.00%) -IGKJ5*01) [11.3.9](1'-112') -Homo sapiens IGKC*01 (113'-219')]; (218-218":219-219":222-222":225-225")-tetrakisdisulfide dimerhuman β-amyloid fibrils depository inhibitorponezumabponezumabimmunoglobuline G2-kappa, anti-[Homo sapiens peptide amyloïdebêta (A bêta) Aβ40], anticorps monoclonal humanisé;chaîne lourde gamma2 (1-442) [VH humanisé (Homo sapiensIGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -Homosapiens IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)],(130-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPAhumanisé (Homo sapiens IGKV2-30*01 (89.00%) -IGKJ5*01)[11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (218-218":219-219":222-222":225-225")-tétrakisdisulfureinhibiteur de la déposition de fibrilles β-amyloïdes humainesinmunoglobulina G2-kappa, anti-[péptido amiloide beta de Homosapiens (A beta) Aβ40], anticuerpo monoclonal humanizado;cadena pesada gamma2 (1-442) [VH humanizada (Homo sapiensIGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -Homosapiens IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)],(130-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPAhumanizada (Homo sapiens IGKV2-30*01 (89.00%) -IGKJ5*01)[11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímer (218-218":219-219":222-222":225-225")-tetrakisdisulfuroinhibidor del depósito de fibrillas β-amiloides humanas1178862-65-1Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGASVKV SCKASGYYTE AYYIHWVRQA PGQGLEWMGR 50IDPATGNTKY APRLQDRVTM TRDTSTSTVY MELSSLRSED TAVYYCASLY 100SLPVYWGQGT TVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS NFGTQTYTCN 200VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP KPKDTLMISR 250TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVSV 300LTVVHQDWLN GKEYKCKVSN KGLPSSIEKT ISKTKGQPRE PQVYTLPPSR 350EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PMLDSDGSFF 400LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK 442Light chain / Chaîne légère / Cadena ligeraDVVMTQSPLS LPVTLGQPAS ISCKSSQSLL YSDAKTYLNW FQQRPGQSPR 50RLIYQISRLD PGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQGTHYP 100VLFGQGTRLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 143-199 256-316 362-42022''-96'' 143''-199'' 256''-316'' 362''-420''Intra-L 23'-93' 139'-199'23'''-93''' 139'''-199'''Inter-H-L 130-219' 130''-219'''Inter-H-H 218-218'' 219-219'' 222-222'' 225-225''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación292, 292''388